As global weight loss drug development enters a heated phase, Cagrilintide, a long-acting amylin analog developed by Danish pharmaceutical giant Novo Nordisk, has attracted significant attention. Recently, Novo Nordisk officially launched a Phase III clinical trial in China for overweight or obese children and adolescents, further expanding the drug's development footprint. However, as a novel peptide drug that works by activating the brain's appetite regulation center, while Cagrilintide demonstrates remarkable weight loss potential, its strict contraindications have also drawn widespread attention from the medical community. Clinical experts have provided an in-depth analysis of the absolute contraindications for this drug and the underlying pathological mechanisms.
Primary Contraindication: History of Medullary Thyroid Carcinoma and MEN2 Syndrome
The most crucial absolute contraindication for Cagrilintide is a personal history of medullary thyroid carcinoma (MTC) or a family history of multiple endocrine neoplasia type 2 (MEN2). This restriction stems from the potential carcinogenic risk exhibited in animal models by long-acting amylin receptor agonists. Although there is currently no conclusive evidence that these drugs directly cause thyroid cancer in humans, for extremely high safety reasons, any individual with a history of such tumors or a genetic predisposition is strictly excluded from the recommended user population.
Absolute Allergy History: Risk of Hypersensitivity Reactions
As with all biologics and peptide drugs, this drug is absolutely contraindicated in patients with a known history of severe hypersensitivity reactions (such as anaphylactic shock, angioedema) to Cagrilintide or any related compounds in its formulations. Repeated administration may trigger an irreversible immune cascade reaction, endangering the patient's life.
Severe Gastrointestinal Disorders: Additive Effects of Gastric Emptying Impairment
One of the core pharmacological mechanisms of Cagrilintide is delaying gastric emptying, thereby prolonging satiety and reducing food intake. Therefore, this drug is relatively or absolutely contraindicated in patients with severe gastrointestinal disorders (especially gastroparesis, severe gastrointestinal motility disorders). If used in such populations, the delayed gastric emptying caused by the drug will have a cumulative effect with the patient's original pathological condition, potentially leading to severe food retention, intractable vomiting, or even intestinal obstruction.
Special Combination Therapy Scenarios: High-Risk Groups for Hypoglycemia
While Cagrilintide rarely causes hypoglycemia when used alone, the risk increases significantly in certain combination therapy scenarios. When patients are simultaneously using insulin or insulin secretagogues (such as sulfonylureas), Cagrilintide alters the rate of nutrient absorption, potentially causing a sudden drop in blood glucose levels in the original hypoglycemic regimen. This scenario is not absolutely contraindicated, but the dosage of hypoglycemic drugs must be readjusted under close monitoring by a professional physician; otherwise, severe iatrogenic hypoglycemia is highly likely.
Currently, the combination formulation of Cagrilintide and semaglutide (CagriSema) is in a critical stage of global multicenter Phase III clinical trials and market approval. The medical community urges that, despite the significant efficacy of new-generation weight-loss drugs, patients must undergo rigorous clinical screening, and weight loss needs should not be prioritized over medication safety.